Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating
factor of fever and neutropenia induced by chemotherapy in patients
with small-cell lung cancer. N Engl J Med. 1991;325:164-170.
Bertini M, Freilone R, Vitolo U, et al. P-VEBEC: a new 8-weekly schedule
with or without rG-CSF for elderly patients with aggressive non-Hodgkin’s
lymphoma (NHL). Ann Oncol. 1994;5:895-900.
de Graaf H, Willemse PHB, Bong SB, et al. Dose intensity of standard
adjuvant CMF with granulocyte colony-stimulating factor for premenopausal
patients with node-positive breast cancer. Oncology. 1996;53:289-294.
Wujcik D. Infection. In: Groenwald SL, Goodman M, Frogge MH, Yarbro
CH, eds. Cancer Symptom Management. Boston, Mass: Jones and Bartlett
Publishers; 1986:289-304.
The Merck Manual of Medical Information—Home Edition Online.
Available at:
http://www.merck.com/pubs/. Accessed February 15,
2002.
Link BK, Budd GT, Scott S, et al. Delivering adjuvant chemotherapy
to women with early-stage breast carcinoma: current patterns of care.
Cancer. 2001;92:1354-1367.
Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity
in adjuvant breast cancer chemotherapy: a nationwide study of commmunity
practices. J Clin Oncol. 2003;21:4524-4531.
Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating
factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.
Am J Med. 2002;112:406-411.
Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships
between circulating leukocytes and infection in patients with acute
leukemia. Ann Intern Med. 1966;64:328-340.
Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant
cyclophosphamide, methotrexate, and fluorouracil in node-positive breast
cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901-906.
Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic
outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology
Group experience. J Clin Oncol. 1986;4:295-305.
Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy.
In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in
Oncology. Philadelphia, Pa: JB Lippincott; 1988:121-141.
Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual
dose intensity in diffuse large-cell lymphoma: results of a tree-structured
survival analysis. J Clin Oncol. 1990;8:963-977.
Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized,
multicenter study to evaluate single administration pegfilgrastim once
per cycle versus daily filgrastim as an adjunct to chemotherapy in patients
with high-risk stage II or stage III/IV breast cancer. J Clin Oncol.
2002;20:727-731.
Green M, Koelbl H, Baselga J. A randomized double-blind multicenter
phase III study of fixed-dose single-administration pegfilgrastim versus
daily filgrastim in patients receiving myelosuppressive chemotherapy.
Ann Oncol. 2003;14:29-35.
Smith TJ et al. Can the Addition of Prophylactic Filgrastim Be Considered Cost Effective in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide? J Clin Oncol. 2006;24:3187-3205
National Comprehensive Cancer Network. Clin Pract Guide Oncol [serial online]. Version 1.2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf. Accessed May 24, 2007.
